Brief: Pharma Equity Group's Reponex Reports Highly Positive Final Results From Phase-2 Clinical Trial Of Co's Patented Drug Candidate RNX-051

Pharma Equity A/S

05/04/2024 10:27

April 5 (Reuters) - Pharma Equity Group A/S  PEGRP.CO :
    * SUBSIDIARY REPONEX PHARMACEUTICALS A/S REPORTS HIGHLY
POSITIVE
FINAL RESULTS FROM PHASE-2 CLINICAL TRIAL OF COMPANY'S PATENTED
DRUG CANDIDATE RNX-051

Source text for Eikon:  ID:nGNEC2T7N 
Further company coverage:  PEGRP.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))